Zepbound
60 articles on Zepbound, researched and written by the Shotlee Editorial Team from primary sources.
Eli Lilly, Novo Nordisk Address Awareness Gap for Medicare’s $50 GLP-1 Program
Learn how the new Medicare GLP-1 Bridge program works, which drugs are covered, and why major pharmaceutical companies are leading the awareness push for the $50 copay initiative.
8 min read
Eli Lilly's Retatrutide Shows Cardiovascular and Diabetic Benefits in Trials
Eli Lilly's investigational drug, retatrutide, has shown promising results in clinical trials, offering substantial weight loss and significant improvements in cardiovascular health and type 2 diabetes management.
7 min read
New Yorkers Are Ordering Peptides Like Takeout – And California Trim Clinic Is Behind It
New York City is experiencing a surge in peptide therapy requests via telehealth platforms. This article explores the most popular compounds, safety protocols, and how to track results effectively.
8 min read
Samsung Biologics Acquires PolyPeptide for $1.8 Billion to Expand Peptide Therapeutics
Samsung Biologics has announced a major acquisition of PolyPeptide Group AG for $1.8 billion, marking a strategic expansion into the rapidly growing peptide therapeutics market, particularly for GLP-1 drugs.
8 min read
New “Trojan Horse” Drug Supercharges Weight Loss in Early Trials
A new hybrid molecule designed by Helmholtz Munich researchers acts as a Trojan horse to deliver metabolic compounds directly into cells, showing superior weight loss in mice compared to standard treatments.
8 min read
MOTS-C: A Peptide for Obesity Beyond GLP-1s?
While GLP-1 agonists have dominated weight loss discussions, a new peptide called MOTS-C is emerging with its own unique potential for tackling obesity and improving metabolic health. This article delves into what MOTS-C is, how it works, and its current research status.
7 min read
Bitter Hops Extract Supplement for Weight Loss
A recent study suggests a bitter hops extract supplement, Amarasate, could aid fat loss and preserve muscle mass, offering a potential alternative or complementary approach to GLP-1 medications.
8 min read
Study Links Hormonal Birth Control Use to Higher Likelihood of Needing Weight Loss Injections
A recent Danish study suggests that women who have used hormonal birth control may be more likely to seek weight loss injections such as Wegovy and Ozempic. This research sheds light on a long-reported, yet often unproven, connection between contraceptives and weight changes.
7 min read
Eli Lilly Prepares FDA Run for ‘Triple-G’ Weight Loss Drug With Phase 3 Data
Eli Lilly has announced positive Phase 3 results for retatrutide, positioning the triple-agonist drug for an FDA filing in 2027 with substantial weight loss outcomes.
7 min read
Ozempic Lowers Calorie Intake For At Least A Year, Even If Hunger Returns, Trial Finds
A new 60-week clinical trial reveals that semaglutide continues to reduce calorie consumption significantly, even when subjective hunger sensations return to baseline levels.
7 min read
The Billion-Dollar Problem Limiting Access to Ozempic, Wegovy, and Zepbound
Despite clinical evidence highlighting the significant health benefits and cost-effectiveness of GLP-1 medications such as Ozempic, Wegovy, and Zepbound, many insurance plans continue to impose restrictions on patient access. This article delves into the financial and practical barriers, as well as the profound consequences for individuals seeking these transformative treatments.
7 min read
Oral GLP-1 Drugs May Quiet the Brain's Food Craving Circuit
New research suggests that oral GLP-1 medications, including those used for weight loss and diabetes, might work by influencing the brain's reward pathways, potentially reducing cravings for enjoyable foods and offering insights into treating substance use disorders.
8 min read
Katie Lee Biegel Shares Update on 'Incredibly Positive' GLP-1 Experience
Food Network personality Katie Lee Biegel opens up about her journey with GLP-1 medications, detailing her 'incredibly positive' experience with weight loss and enhanced well-being.
10 min read
Peptides, GLP-1s, and MAHA: A New Era in Wellness
The world of wellness is rapidly evolving, with groundbreaking advancements in peptide therapy and GLP-1 medications offering new avenues for health management and weight loss. This article delves into the science behind these innovations, explores the potential of 'MAHA' (Maximum Healthspan Aging), and discusses how individuals can navigate this exciting new frontier.
9 min read
Novo Nordisk Sues Eli Lilly Over Which GLP-1 Sheds the Most Pounds
Novo Nordisk has filed a federal lawsuit against Eli Lilly, alleging deceptive advertising regarding the comparative weight loss efficacy of Zepbound and Wegovy. The dispute centers on dosage comparisons and clinical trial data interpretation.
8 min read
Fat Loss with GLP-1s, Muscle Loss Concerns: What Users Need to Know
GLP-1 medications are powerful tools for weight loss, but concerns are emerging about potential muscle mass loss. This article delves into what users need to know about preserving lean body mass and maintaining cardiorespiratory fitness alongside fat reduction.
7 min read
The New Drug Melting Body Fat From 38% To 22% — And The Side Effects Patients Are Ignoring
A detailed look at the case of Gary Anderton, who achieved significant weight loss using unregulated peptides, and the critical safety risks associated with this trend.
8 min read
China Adds Second GLP-1 Diabetes Drug to Essential Medicine List
China includes injectable semaglutide on its National Essential Drug List, improving access for diabetes patients while excluding obesity indications from the policy.
7 min read
Peptides: Lab Finds Issues in 30% of Vials as FDA Panel Considers Looser Rules
Peptides are rapidly gaining traction for various health and wellness claims, but a recent lab analysis revealed significant quality control issues in a substantial percentage of tested vials. As the FDA panel prepares to discuss potentially easing restrictions, understanding the risks and the science behind these compounds is crucial.
7 min read
Compounded Ozempic and Zepbound Still Widely Available After Shortages End
Despite the FDA declaring an end to drug shortages for popular weight loss medications, a new study finds compounded versions remain easily accessible. Understanding the safety implications and regulatory landscape is crucial for patient health.
8 min read
Novo Nordisk Sues Eli Lilly, Alleging Misleading Advertising of Obesity Drugs
Novo Nordisk has filed a lawsuit against Eli Lilly in New Jersey, claiming deceptive advertising regarding GLP-1 and dual-agonist weight loss medications.
7 min read
Study Links GLP-1 Medications To Rare Vision Issue
New research indicates a possible association between GLP-1 medications, commonly prescribed for type 2 diabetes and weight management, and a rare but serious vision issue. This article explores the study's findings, potential implications, and expert recommendations.
6 min read
Novo Nordisk Sues Eli Lilly Over GLP-1 Advertising Claims in Legal Battle
Novo Nordisk has filed a lawsuit against Eli Lilly in the U.S. District Court for the District of New Jersey, alleging false advertising regarding GLP-1 weight loss medications.
7 min read
US Regulators Consider Controversial Peptides Backed by RFK Jr.
The US Food and Drug Administration is evaluating the use of seven peptides, increasingly marketed for wellness and medical conditions. This review comes amidst soaring popularity, celebrity endorsements, and significant debate over their safety and efficacy.
8 min read
Rosie O'Donnell: Mounjaro Changed My Life After Losing 30kg
Talk show host Rosie O'Donnell shares her candid experience with Mounjaro, detailing her 30kg weight loss, Type 2 diabetes management, and the physical consequences of rapid fat loss.
12 min read
Ozempic Maker Novo Nordisk Sues Eli Lilly Over 'Materially Misleading' Ads
Novo Nordisk has filed a lawsuit against Eli Lilly, alleging deceptive advertising regarding weight-loss drugs. This legal battle highlights the intense competition between semaglutide and tirzepatide.
9 min read
GLP-1s for Teen Weight Loss: A New Treatment Trend?
GLP-1 medications are rapidly changing obesity care for teens and young adults, with a notable shift away from bariatric surgery. This article delves into the latest research, potential benefits, and important considerations for this emerging trend.
7 min read
Jim Cramer on Eli Lilly Amid Rival's GLP-1 Lawsuit
Jim Cramer weighs in on Eli Lilly's position in the GLP-1 market following a lawsuit from competitor Novo Nordisk, analyzing the situation for investors.
7 min read
Medicare's New GLP-1 Weight-Loss Drug Program: What to Know
Medicare is launching a new pilot program to increase access to GLP-1 medications for weight loss, offering a $50 monthly copay for eligible beneficiaries. This marks a significant step in covering obesity as a medical condition.
9 min read
Amy Schumer Shows Off Ongoing Weight Loss, Says C-Section Scar Makes Her a 'Warrior'
Comedian Amy Schumer discusses her 50-pound weight loss journey, Cushing syndrome diagnosis, and C-section recovery in a candid new update.
10 min read
Plus-Size Swimsuit Model on Inclusivity Amidst GLP-1 Medications
Plus-size model Hunter McGrady shares her concerns about a perceived decline in fashion inclusivity, particularly in the context of the growing popularity of GLP-1 weight loss medications.
7 min read
Which GLP-1 Works Best? New Meta-Study Puts Medications Head-to-Head
A comprehensive meta-analysis from the University of Georgia compares three major GLP-1 medications. Discover which drug offers the highest weight loss efficacy and what the data means for patients.
8 min read
Peptide Hype: Do They Live Up to the Claims for Skin and Wellness?
From skincare routines to GLP-1 weight loss medications, peptides are everywhere. But do they deliver on their promises for skin health, longevity, and recovery? This article delves into the science and the trend.
9 min read
What is the viral 'natural Ozempic' drink?
A viral trend promoting a 'natural Ozempic' drink made with gelatin and water is circulating on social media. This article delves into what the drink is, its purported benefits, and the expert opinions on its role in weight management.
6 min read
It's Called 'Nature's Ozempic', But Should You Take Psyllium Husk?
Psyllium husk is gaining viral attention for its digestive and metabolic benefits. But is it truly a weight loss solution comparable to GLP-1 medications? We break down the evidence.
8 min read
People Taking GLP-1 Weight Loss Drugs Like Ozempic and Wegovy Started Moving Less
New data presented at ENDO 2026 reveals a paradox: patients on GLP-1 medications like Ozempic and Wegovy reduced their physical activity despite losing weight.
8 min read
Yes, GLP-1s Make You Thinner. But Do They Make You Freer?
While GLP-1 drugs like Ozempic and Wegovy offer significant medical benefits, their rise raises critical questions about freedom, body image, and the cultural pressure to be thinner.
8 min read
Ozempic and Similar Weight-Loss Medications Linked to 30% Lower Breast Cancer Risk
A major study from Penn Medicine reveals a potential link between GLP-1 medications like Ozempic and a significant reduction in breast cancer risk, offering new hope for preventive care.
7 min read
GLP-1 Weight-Loss Drugs Linked to Lower Risks of Addiction and Overdose
Explore the groundbreaking research linking GLP-1 medications, including Ozempic, Wegovy, Mounjaro, and Zepbound, to a reduced risk of substance use disorders and fewer addiction-related emergencies.
8 min read
Bariatric Surgery Shows 5x More Weight Loss Than GLP-1s in Real-World Study
A groundbreaking real-world comparison study presented at the ASMBS 2025 Annual Scientific Meeting found that bariatric surgery resulted in approximately five times more weight loss compared to popular GLP-1 receptor agonist medications over a two-year period. This research highlights important considerations for patients and healthcare providers navigating weight management options.
7 min read
Mounjaro's Impact on Food Cravings: A Case Study
A groundbreaking case study involving deep brain activity recordings has shed light on how tirzepatide, known as Mounjaro and Zepbound, impacts the brain's reward center and its connection to food cravings and loss of control eating.
8 min read
Managing Ozempic and Wegovy Weight Loss Side Effects: Nausea and Beyond
New research is shedding light on how GLP-1 medications, including popular drugs like Ozempic and Wegovy, influence brain pathways that control nausea, thirst, and reward-driven behaviors. This article delves into these findings and discusses potential strategies for managing common side effects.
7 min read
The Next Ozempic: A 4-in-1 Breakthrough for Lasting Weight Loss
While Ozempic and similar GLP-1 agonists have revolutionized weight management, new research from Tufts University is exploring a novel 4-in-1 peptide that targets four hormone receptors for potentially greater efficacy and fewer side effects, moving closer to the gold standard of bariatric surgery.
6 min read
GLP-1 Medications for Obesity: Experts See a Broader Revolution Ahead
While GLP-1 receptor agonists have significantly advanced obesity treatment, specialists highlight the evolving landscape of comprehensive, personalized care that integrates various therapeutic strategies.
6 min read
Ozempic and Wegovy Linked to Reduced Violent Behavior in New Study
Beyond their well-known benefits for weight loss and diabetes management, popular GLP-1 medications such as Ozempic and Wegovy are now being studied for their potential impact on violent behavior. Emerging research from Rutgers University indicates a surprising link between these drugs and a reduction in actions associated with violence.
6 min read
Ozempic's Oral Twin: A Needle-Free Weight Loss Revolution Arrives?
A new era in weight management may be dawning as an oral medication, mirroring the efficacy of popular injectables like Ozempic, is poised for approval. This development promises a more accessible and convenient path to weight loss for millions.
7 min read
Eli Lilly's Foundayo: A New Daily Pill Outperforming Oral Semaglutide
A groundbreaking Phase 3 trial reveals that Eli Lilly's new daily oral medication, orforglipron (Foundayo), demonstrates superior efficacy in lowering blood sugar and promoting weight loss compared to existing oral semaglutide treatments for individuals with Type 2 diabetes. This development marks a significant step forward in non-injectable peptide therapies for metabolic health.
6 min read
Wegovy and the Wedding Dress: The Hidden Costs of Rapid Weight Loss
Prescription weight loss drugs are becoming a wedding staple, but medical experts warn of serious side effects and ethical concerns behind the trend.
9 min read
Beyond the Pen: Navigating Weight Loss & Societal Pressures with GLP-1s
Discover how GLP-1 medications are transforming lives, offering significant weight loss and improved self-esteem. This article delves into the personal victories and the broader societal implications, including the persistent pressures on women's bodies.
8 min read
Beyond Ozempic: A Dark Twist on Weight Loss Obsession
The rise of GLP-1 agonists has sparked a global conversation about weight loss. This article delves into the cultural phenomenon, its psychological underpinnings, and how a new horror film, 'Saccharine,' offers a chilling commentary.
7 min read
Ozempic, Wegovy, Mounjaro: Who Benefits When Obesity is Labeled a Disease?
As GLP-1 medications like Ozempic, Wegovy, and Mounjaro gain prominence, the medical community and pharmaceutical giants are increasingly framing obesity as a chronic disease. This article delves into the multifaceted implications of this classification, examining its impact on treatment, policy, and patient perception, while questioning who truly benefits from this shift.
7 min read
Semaglutide's Essential Status in China: A Leap for Diabetes Care
China's decision to include semaglutide on its National Essential Drug List marks a significant step in improving diabetes management across the nation, promising greater accessibility for millions.
6 min read
Ozempic & Wegovy Safety: The Yale Study on Online Prescribing
A recent JAMA study reveals significant gaps in medical oversight for online GLP-1 prescriptions. Discover the risks and how to ensure safe access to weight loss medications.
7 min read
Beyond the Jab: A Natural Weight Loss Journey and Its Hidden Costs
Melanie Sivier chose the 'hard way' over bariatric surgery or new GLP-1 medications like Ozempic and Mounjaro, shedding nine dress sizes through dedication. Her story highlights the profound commitment required for sustainable change, and the often-overlooked physical aftermath.
6 min read
Ozempic, Mounjaro & More: Yale Study Exposes Risky Online GLP-1 Prescribing
New research from Yale University highlights critical gaps in the online prescribing of GLP-1 medications, raising serious concerns about patient safety and regulatory oversight.
8 min read
Ozempic & Wegovy Online: The Risky Rush to Bypass Doctor Consultations
The surge in GLP-1 medications for weight loss has led to a concerning trend: many online pharmacies are prescribing these powerful drugs with minimal to no doctor consultation, putting patients at significant risk.
6 min read
Beyond the Hype: Understanding Peptides for Weight Loss and Health
Curious about peptides and their role in weight loss, cholesterol management, and overall health? This article breaks down what peptides are, how they work, and what the science says about popular options like GLP-1 agonists.
7 min read
Beyond the Hype: Understanding GLP-1s and Weight Management
The rise of GLP-1 medications has revolutionized weight management. This comprehensive guide delves into semaglutide, tirzepatide, and other peptide therapies, offering insights into their efficacy, potential side effects, and how to track your progress effectively.
7 min read
Beyond Weight Loss: How GLP-1s Like Ozempic May Reshape Your Inner World
GLP-1 medications have revolutionized weight loss, but are they also changing how we feel, think, and connect? This article delves into the emerging 'Ozempic Personality' and the science behind potential mood and behavioral shifts.
9 min read
Ozempic, Wegovy & Mounjaro: What Your Bones & Joints Need to Know
Millions are experiencing significant weight loss with GLP-1 medications. But what happens to your bones, joints, and muscles as the pounds drop? An orthopedic surgeon shares crucial insights.
7 min read